Barclays’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-22,900
| Closed | -$3.02M | – | 5378 |
|
|
2024
Q1 | $3.02M | Sell |
22,900
-1,800
| -7% | -$225K | ﹤0.01% | 2225 |
|
|
2023
Q4 | $3.01M | Buy |
+24,700
| New | +$2.76M | ﹤0.01% | 2560 |
|
|
2020
Q2 | – | Sell |
-1,133
| Closed | -$111K | – | 6345 |
|
|
2020
Q1 | $111K | Sell |
1,133
-22,969
| -95% | -$3.01M | ﹤0.01% | 4731 |
|
|
2019
Q4 | $3.5M | Buy |
24,102
+16,171
| +204% | +$2.23M | ﹤0.01% | 2396 |
|
|
2019
Q3 | $1.06M | Sell |
7,931
-3,296
| -29% | -$426K | ﹤0.01% | 3624 |
|
|
2019
Q2 | $1.28M | Sell |
11,227
-2,060
| -16% | -$241K | ﹤0.01% | 3428 |
|
|
2019
Q1 | $1.65M | Sell |
13,287
-54,796
| -80% | -$6.23M | ﹤0.01% | 2789 |
|
|
2018
Q4 | $6.86M | Buy |
68,083
+45,732
| +205% | +$5.14M | 0.01% | 1385 |
|
|
2018
Q3 | $2.85M | Buy |
22,351
+18,128
| +429% | +$2.16M | ﹤0.01% | 2470 |
|
|
2018
Q2 | $457K | Sell |
4,223
-7,828
| -65% | -$852K | ﹤0.01% | 4035 |
|
|
2018
Q1 | $1.28M | Sell |
12,051
-4,017
| -25% | -$467K | ﹤0.01% | 2933 |
|
|
2017
Q4 | $1.88M | Buy |
16,068
+11,742
| +271% | +$1.33M | ﹤0.01% | 2490 |
|
|
2017
Q3 | $492K | Buy |
4,326
+4,017
| +1,300% | +$464K | ﹤0.01% | 3645 |
|
|
2017
Q2 | $39K | Sell |
309
-13,596
| -98% | -$1.61M | ﹤0.01% | 5489 |
|
|
2017
Q1 | $1.65M | Sell |
13,905
-13,184
| -49% | -$1.49M | ﹤0.01% | 2279 |
|
|
2016
Q4 | $2.71M | Buy |
27,089
+17,819
| +192% | +$1.91M | ﹤0.01% | 1876 |
|
|
2016
Q3 | $1.17M | Sell |
9,270
-618
| -6% | -$76.4K | ﹤0.01% | 2487 |
|
|
2016
Q2 | $1.16M | Sell |
9,888
-23,175
| -70% | -$2.62M | ﹤0.01% | 2491 |
|
|
2016
Q1 | $3.4M | Buy |
33,063
+20,806
| +170% | +$2.01M | 0.01% | 1472 |
|
|
2015
Q4 | $1.21M | Sell |
12,257
-4,223
| -26% | -$413K | ﹤0.01% | 2433 |
|
|
2015
Q3 | $1.49M | Buy |
16,480
+4,532
| +38% | +$454K | ﹤0.01% | 2378 |
|
|
2015
Q2 | $1.26M | Sell |
11,948
-88,271
| -88% | -$9.77M | ﹤0.01% | 2669 |
|
|
2015
Q1 | $11.4M | Buy |
100,219
+95,893
| +2,217% | +$10.9M | 0.01% | 993 |
|
|
2014
Q4 | $475K | Sell |
4,326
-69,525
| -94% | -$7.33M | ﹤0.01% | 3905 |
|
|
2014
Q3 | $7.17M | Sell |
73,851
-12,257
| -14% | -$1.21M | 0.01% | 1452 |
|
|
2014
Q2 | $8.61M | Sell |
86,108
-54,590
| -39% | -$5.33M | 0.01% | 1272 |
|
|
2014
Q1 | $12.8M | Buy |
140,698
+12,669
| +10% | +$1.17M | 0.01% | 971 |
|
|
2013
Q4 | $11.6M | Buy |
128,029
+53,354
| +71% | +$4.62M | 0.01% | 1145 |
|
|
2013
Q3 | $5.95M | Buy |
74,675
+2,369
| +3% | +$186K | 0.01% | 1544 |
|
|
2013
Q2 | $5.26M | Buy |
+72,306
| New | +$5.41M | 0.01% | 1586 |
|
Other funds holding ZBH
VCM
VPM
Barclays's ZBH Position: Q1 2026 in Review
Barclays reduced its Zimmer Biomet (ZBH) stake by 6.9% in Q1 2026, selling an estimated $2.92M and leaving 426,256 shares worth $38.5M. The position accounts for 0.01% of the portfolio, ranked #820.
Barclays first reported a position in ZBH in Q2 2013 and has held it in 52 quarters since. The position peaked at $120M in Q3 2023. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.
- Barclays held 426,256 shares of Zimmer Biomet worth $38.5M as of Q1 2026.
- Barclays sold 31,773 Zimmer Biomet shares in Q1 2026, an estimated $2.92M.
- Zimmer Biomet made up 0.01% of Barclays's portfolio in Q1 2026, its #820 holding.
- Barclays first reported a position in Zimmer Biomet in Q2 2013 and has held it in 52 quarters since.
- Barclays's Zimmer Biomet position peaked at $120M in Q3 2023.
- 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.